EGFR antibody

Catalog No. ABIN371623

Product Details anti-EGFR Antibody

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Reactivity: Human

Host: Rat

Clonality: Monoclonal

Conjugate: This EGFR antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro))

Specificity: This antibody reacts with human EGFR (150 kDa). It reacts specifically with the EGFR but does not react with Her-2 recombinant protein.

Characteristics: Synonyms: Epidermal growth factor receptor, EGF Receptor, erbB-1, c-ErbB-1, Receptor tyrosine-proteinkinase erbB-1, Proto-oncogene c-ErbB-1

Purification: Purified

Immunogen: Recombinant human EGFR.

Clone: SB41a

Isotype: IgG2a

Application Details

Application Notes: Western Blot: < / = 1-2 μg/mL. Immunohistochemistry (FS or cultured and Methanol-Fixed Cell Lines): 10 μg/mL
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 0.1 mg/mL

Buffer: 100 mM Borate buffered saline, pH 8.0 without preservatives.

Preservative: Without preservative

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

Expiry Date: 12 months

Target Details for EGFR

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Alternative Name: EGFR / ERBB1 (EGFR Products)

Synonyms: C-erb antibody, CG10079 antibody, D-EGFR antibody, D-Egf antibody, DEGFR antibody, DER antibody, DER flb antibody, DER/EGFR antibody, DER/faint little ball antibody, DER/top antibody, DER/torpedo antibody, DER1 antibody, DEgfr antibody, Degfr antibody, Der antibody, DmHD-33 antibody, Dmel\\CG10079 antibody, EFG-R antibody, EGF-R antibody, EGFR antibody, EGFr antibody, EGfr antibody, EK2-6 antibody, Egf antibody, Egf-r antibody, EgfR antibody, El antibody, Elp antibody, Elp-1 antibody, Elp-B1 antibody, Elp-B1RB1 antibody, HD-33 antibody, TOP antibody, Torpedo/DER antibody, Torpedo/Egfr antibody, c-erbB antibody, d-egf-r antibody, dEGFR antibody, dEGFR1 antibody, dEgfr antibody, der antibody, egfr antibody, flb antibody, l(2)05351 antibody, l(2)09261 antibody, l(2)57DEFa antibody, l(2)57EFa antibody, l(2)57Ea antibody, mor1 antibody, top antibody, top/DER antibody, top/flb antibody, torpedo/Egfr antibody, torpedo/egfr antibody, EGFR12 antibody, EGFR15 antibody, egfr1 antibody, Erbb2 antibody, ERBB antibody, ERBB1 antibody, HER1 antibody, PIG61 antibody, mENA antibody, ErbB-1 antibody, Errp antibody, 9030024J15Rik antibody, AI552599 antibody, Erbb antibody, Errb1 antibody, Wa5 antibody, wa-2 antibody, wa2 antibody, epidermal growth factor receptor antibody, Epidermal growth factor receptor antibody, epidermal growth factor receptor a (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) antibody, EGFR antibody, Egfr antibody, egfra antibody, egfr1 antibody, LOC5564544 antibody

Background: Epidermal growth factor receptor (EGFR) is a transmembrane receptor for epidermal growth factor (EGF). It is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB -1), HER2/c-neu (ErbB-2) Her 3 (ErbB-3 and Her 4 (ErbB-4). EGFR exists on the cell surface as inactive monomers and is activated by binding of its specific ligands, including EGF, transforming growth factor alpha (TGFalpha), or others. Upon activation, EGFR can pair with another EGFR to form an active homodimer or an EGFR may pair with another member of the ErbB receptor family, such as Her 2/c-neu, to create a heterodimer. Evidence also suggests that a cluster of active EGFR can form. (Ref.1-3) The binding of ligand stimulates the intrinsic protein-tyrosine kinase activity of EGFR which initiates a signal transduction cascade leading to DNA synthesis and cell proliferation. The kinase activity can also result in autophosphorylation of the five tyrosine residues in the C-terminal domain of EGFR. Autophosphorylation elicits downstream activation and signaling events of other proteins that are often distinct from those activated by the kinase domain of EGFR. Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation. The kinase domain of EGFR can also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and can itself be activated in this manner. Mutations that lead to EGFR overexpression or overactivity have been associated with many common solid human squamous cell carcinomas including breast, brain, bladder, lung, gastric, head and neck, esophagus, cervix, vulva, ovary, and endometrium. (Ref.4-7) EGFR and ErbB -2 are particularly important in breast cancer because increased production or activation has been associated with poor prognosis. Tumor aggressiveness and patient outcome can be directly correlated to the production levels. Inhibitors of EGFR represent an emerging new class of anti-cancer drugs that target the underlying molecular changes involving oncogenes and tumor suppressor genes, genes that play critical roles in the conversion of normal cells into a cancerous state.Synonyms: EGF Receptor, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, c-ErbB-1, erbB-1

Gene ID: 1956

UniProt: P00533

Pathways: NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins